Abstract: Phosphate retention and hyperphosphataemia are associated with increased mortality in patients with chronic kidney disease (CKD). We tested the use of cross-linked iron chitosan III (CH-FeCl) as a potential phosphate chelator in rats with CKD. We evaluated 96 animals, divided equally into four groups (control, CKD, CH-FeCl and CKD/CH-FeCl), over 7 weeks. We induced CKD by feeding animals an adenine-enriched diet (0.75% in the first 4 weeks and 0.1% in the following 3 weeks). We administered 30 mg/kg daily of the test polymer, by gavage, from the third week until the end of the study. All animals received a diet supplemented with 1% phosphorus. Uraemia was confirmed by the increase in serum creatinine in week 4 (36.24 AE 18.56 versus 144.98 AE 22.1 lmol/L; p = 0.0001) and week 7 (41.55 AE 22.1 versus 83.98 AE 18.56 lmol/L; p = 0.001) in CKD animals. Rats from the CKD group treated with CH-FeCl had a 54.5% reduction in serum phosphate (6.10 AE 2.23 versus 2.78 AE 0.55 mmol/L) compared to a reduction of 25.6% in the untreated CKD group (4.75 AE 1.45 versus 3.52 AE 0.74 mmol/L, p = 0.021), between week 4 and week 7. At week 7, renal function in both CKD groups was similar (serum creatinine: 83.98 AE 18.56 versus 83.10 AE 23.87 lmol/L, p = 0.888); however, the CH-FeCl-treated rats had a reduction in phosphate overload measured by fractional phosphate excretion (FEPi) (0.71 AE 0.2 versus 0.4 AE 0.16, p = 0.006) compared to the untreated CKD group. Our study demonstrated that CH-FeCl had an efficient chelating action on phosphate.
Approximately 70% of patients with chronic kidney disease (CKD) have impaired phosphorus metabolism, which contributes to high cardiovascular mortality in this population [1, 2] . As kidney dysfunction progresses and renal phosphate excretion is impaired, fractional excretion of phosphate (FEPi) and fibroblast growth factor 23 (FGF23) increase at early phases of CKD, while phosphataemia and parathyroid hormone (PTH) levels are elevated at later stages. These changes have been recognized as the most common indicators of mineral-bone disorder that is associated with CKD (CKD-MBD) [3] [4] [5] [6] . The current treatment approach aims to reduce the phosphate overload through dietary restriction and the use of substances with phosphate-chelating power in the intestinal tract [4, 7] . Calcium-based phosphate chelators, although widely used, have been progressively replaced by non-calcium chelators, such as sevelamer and lanthanum, due to their associated increased risk of vascular calcification [8] [9] [10] [11] [12] [13] . Recently, the emergence of novel alternatives, such as iron-based chelators, that is, ferric citrate and sucroferric oxidation (PA21), has expanded the treatment options for CKD-MBD [14] [15] [16] [17] .
A new insoluble complex of chitosan and iron (III) chloride, the cross-linked iron chitosan III (CH-FeCl), has been investigated as a possible chelator with the advantages of the adsorption power of chitosan. CH-FeCl combines the chelation properties of chitosan and iron, without the risk of increased iron availability and consequent toxicity. This compound has been shown to reduce phosphate absorption in the intestine of diabetic rats with hyperphosphataemia induced by diet phosphorus overload [18] [19] [20] . However, in those studies, the animals did not have CKD or CKD-MBD, which limits the clinical usefulness of the results.
Our study aimed to evaluate the power of the CH-FeCl complex as a phosphate chelator in an experimental model of CKD with confirmed loss of renal function that mimics phosphate retention and hyperphosphataemia secondary to CKD in human beings. 3 , and vacuum-dried. This product was then added to a 15% glutaraldehyde solution in acetone (Merck, Cotia, SP, Brazil) for 24 hr, filtered and washed with water to remove excess glutaraldehyde. The resulting polymer was characterized according to the literature [21] . The iron content was 80 mg/g, as determined by the spectrophotometric method with 1,10-phenanthroline as a complexing agent and a Shimadzu UV1600 spectrophotometer (Shimadzu, Kyoto, Japan). The entire procedure was carried out at the Universidade do Vale do Itaja ı (UNIVALI) Chemistry Laboratory.
Materials and methods

Animals
Experimental model and design. After a week of acclimatization, 96 rats were divided into four groups: control, CH-FeCl, CKD and CKD/ CH-FeCl. Uraemia was induced in the CKD and CKD/CH-FeCl groups (n = 48 animals) by feeding the animals an adenine-enriched diet (Pragsoluc ßões Biociências, Ja u, SP). We included 0.75% adenine in the diet until week 4 to induce CKD [22, 23] . In the next 3 weeks, we used 0.1% adenine to maintain CKD, as previously described [24] . We added the maintenance phase [24] to the original protocol of 0.75% adenine for 4 weeks [22, 23] in order to prevent renal function recovery that can occur in some animals according to a pilot study (data not shown), and to better mimic CKD-MBD [24] . The control and CH-FeCl groups (n = 48 animals) were fed a standard diet (Pragsoluc ßões Biosciências, Ja u, Brazil) over the entire 7 weeks of the experiment. All diets were enriched in phosphorus (1% total phosphorus). Body-weight and food intake were measured weekly.
Eight animals from each group were killed at the fourth, sixth and seventh weeks to monitor disease progression. On the previous day, animals were kept in metabolic cages and urine was collected for 24 hr. Animals were anaesthetized by an intraperitoneal injection of 10 mg/kg xylazine and 90 mg/kg ketamine (K€ onig SA, Avellaneda, Argentina), and blood samples were obtained by heart puncture, without evidence of significant haemolysis, followed by diaphragm rupture [25] .
Urine samples were centrifuged at 3000 g for 10 min. in a refrigerated centrifuge (Sorvall, Suwanee, GA, USA). Blood was also centrifuged under the same conditions to obtain the serum. Both types of samples were then stored in cryogenic tubes at À80°C (Thermo Scientific, Suwanee, GA, USA) until further analysis.
CH-FeCl: CH-FeCl was administered daily by gavage from the third week until the end of the study at a dosage of 30 mg/kg daily [19] , whereas animals in the control and CKD groups received gavage with a 0.9% NaCl physiological solution over the same period.
Biochemical analysis and renal function. Levels of serum and urinary creatinine, serum and urinary phosphate, total serum calcium and total serum iron were measured with a Labmax Progress automatic analyser (Labtest Diagnostica S.A., Lagoa Santa, MG, Brazil).
Statistical analysis. Data normality was assessed by the Shapiro-Wilk test and is presented as mean AE standard deviation. Comparison between groups was performed with Student's t-test, whereas the analysis of variance (ANOVA) was used for comparisons of more than two groups, followed by the Bonferroni test. The difference was considered significant when p < 0.05. All analyses were carried out with the IBM SPSS Statistics 21 program (SPSS, Chicago, IL, USA).
Results
Of the initial group of 96 animals, four died during the study: one from the CKD group during the third week, one from the CH-FeCl group during the fourth week and two from the CHFeCl group during the sixth week. Weight, food intake and the biochemical parameters analysed were not affected by the use of CH-FeCl during the treatment period ( fig. 1 and  table 1 ).
After the introduction of adenine into the diet, we observed weight loss in the animals and significant changes in biochemical parameters. In the CKD group, there was a reduction in renal function, measured by increased creatinine levels at week 4 (144.
Serum creatinine (p = 0.001), phosphate (p = 0.001), calcium (p = 0.02) and FEPi (p = 0.0001) values were higher in the CKD group than in the control group by week 7 (table 1) .
Conversely, when we evaluated serum phosphate variation between week 4 and week 7 in the CKD/CH-FeCl group, we observed a significant decline in serum phosphate of 54.5% in this group (6.10 AE 2.23 versus 2.78 AE 0.55 mmol/L) compared to the untreated CKD group, which showed a 25.6% reduction (p = 0.021; 4.75 AE 1.45 versus 3.52 AE 0.74 mmol/ L) ( fig. 3) .
We observed that the CKD group treated with CH-FeCl had significantly lower FEPi values (0.71 AE 0.20 versus 0.40 AE 0.16, p = 0.006) compared to those of the CKD group at week 7; however, there were no significant differences in renal function between the two groups (serum creatinine: 83.98 AE 18.56 versus 83.10 AE 23.87 lmol/L, p = 0.888) (table 1) .
There was no difference in total serum iron values between the groups at week 7 (table 1).
Discussion
Loss of renal function leads to the progressive retention of certain electrolytes, such as phosphate. When the glomerular filtration rate is below 20 mL/min./1.73 m 2 , kidneys increase the rate of urinary phosphate excretion, indicated by FEPi, to maintain the serum phosphate balance [26] . Thus, substances that chelate intestinal phosphate, by reducing its absorption and bioavailability, lead to a subsequent reduction in the excretion of urinary phosphate and FEPi [27, 28] . Although calcium-based chelators are often used in hyperphosphataemia therapy, mainly due to their greater availability and lower cost compared to non-calcium chelators, their association with high serum calcium levels and the risk of metastatic calcification warrants the development of calcium-free chelators. On the other hand, the available non-calcium compounds, such as sevelamer and lanthanum carbonate, also have limitations due their high costs and the absence of proven safety in long-term use [29, 30] . In our study, we demonstrated that the CH-FeCl polymer, a calcium-free, low-cost, and non-absorbable compound, significantly reduced the levels of serum phosphate in rats with CKD induced by an adenine-enriched diet. The drug used in our study is a complex of cross-linked chitosan and Fe (III). The cross-linking process with glutaraldehyde renders the polymer insoluble at the acidic pH in the stomach, preventing the release of iron [20] , which, as a transition metal, can establish a strong link to phosphate. The phosphate-chelating capacity of this non-absorbable polymer was demonstrated in previous animal and in vitro studies, with a serum phosphate reduction of 20%-40%, without promoting changes in serum iron levels [17] [18] [19] [20] . However, although these animals presented elevated phosphate levels, they did not develop CKD, contrary to the animals in our study.
Our experimental model reproduced CKD phase 4, as classified by the National Kidney Foundation [31] , with tubulointerstitial involvement, as indicated by polyuria ( fig. 2) .
Anaemia was present in the animals with CKD, but serum iron levels did not change with the introduction of the chelator, demonstrating the non-absorption of iron in the intestine.
The use of phosphate chelators is common and necessary in patients with dialytic CKD, as diet and dialysis alone are insufficient to control hyperphosphataemia. However, the capacity of these compounds to reduce phosphataemia is variable, with studies demonstrating a reduction in phosphate between 20% and 50%. In addition to the differing efficacies of the compounds, the adherence of patients to the use of phosphate chelators is also known to vary, making the maintenance of phosphate homoeostasis a constant challenge [32] [33] [34] [35] [36] [37] . Recently, iron-based drugs have been shown to promote a greater reduction in serum phosphate levels than the previously used chelators without causing calcium overload, making this class of drugs the target of studies to evaluate the impact on mortality in patients with CKD [38, 39] . In the last week of our study, animals with CKD treated with CH-FeCl Fig. 1 . Food intake (A) and body-weight (B). Treatment with the cross-linked iron chitosan III (CH-FeCl) complex did not affect any of these parameters, either in the animals in the chronic kidney disease (CKD) or those in the control groups. In the CKD groups (with or without CHFeCl), there was a reduction in weight gain and food intake until week 4, during which time the animals were fed with a 0.75% adenine diet. After week 4, with the reduction in the adenine concentration to 0.1%, food intake and weight gain were recovered in the CKD groups compared to the control groups. Twenty-four animals were studied in each group, and eight animals from each group were killed at weeks 4, 6 and 7. Values are expressed as mean AE S.D. Table 1 . Haemoglobin and biochemical data: Laboratory parameters of the uraemic and non-uraemic rats treated and not treated with CH-FeCl at the end of 7 weeks. had 19% lower serum phosphate values than untreated CKD animals (table 1) . This difference has been considered relevant in clinical studies, as it shows an association with improvement in CKD-MBD markers, possibly reducing the risk of vascular calcification [14, 36, 37, 40, 41] . Furthermore, in the present study, the animals with CKD treated with CH-FeCl also showed a significant 43% reduction in FEPi compared to untreated CKD animals, indicating a reduction in kidney phosphate overload consistent with lower phosphate intestinal absorption and therefore, effective phosphate chelator activity (table 1) . Notably, the two groups presented with similar levels of renal dysfunction. The dose of CH-FeCl complex used in this study that was sufficient to produce a phosphate-chelating effect was equivalent to approximately 2 g/day for a person weighing 70 kg. This is half the typical dose of other chelators, such as sevelamer, calcium carbonate or acetate, bixalomer, and even PA21, used to reduce phosphataemia [33, 34, 38] . These data are of great importance when evaluating the treatment of patients with chronic conditions, as the possibility of reducing the dose or number of daily pills or tablets can increase adherence to treatment and improve quality of life in patients with CKD [42, 43] . However, the results obtained with this dose need to be confirmed in larger studies in human beings.
Although our study had a longitudinal design, the variables evaluated were not collected through repeated measures in the same individual. Thus, the measurements performed in the studied groups at different times are subject to a potential interference from between-group heterogeneity throughout the follow-up. The partial recovery of renal function that was observed in CKD animals, even after the modification of the original CKD model by introducing adenine overload and the severe bone disease induced by this model, led to phosphate and calcium removal from the bone. This may explain why the difference in the serum phosphate levels between the CKD and CKD/CH-FeCl groups was clinically but not statistically significant.
In conclusion, we showed that treatment with a low dose of the CH-FeCl polymer had an effective phosphate chelation action by reducing intestinal phosphate absorption in uraemic rats. It would be interesting to test this compound in studies with human beings to investigate its efficacy, safety and impact on mortality in patients with CKD. 
